TQ Course | Innovations in Glaucoma: Next Generation Technology, Medications, and Delivery (Nashville 2021) by Optometric Education Consultants | Nov 22, 2021 | 2021 Nashville, TQ Courses | 0 comments HiddenInnovations in Glaucoma: Next Generation Technology, Medications, and DeliveryHiddenDate (Hidden) MM slash DD slash YYYY 1. Studies by Weinreb et al have shown that IOP:* a. Is traditionally higher during waking hours b. Is traditionally higher during nocturnal/sleeping hours c. Is traditionally lower during nocturnal/sleeping hours d. Is traditionally the same during waking hours and nocturnal/sleeping hours 2. Recent studies have shown that measuring IOP with this technology may be more accurate than previous options available:* a. Goldmann applanation tonometery (GAT) b. Correcting Applanation Tonometer Surface (CATS) c. Rebound Tonometery d. Non-contact Tonometery 3. A current IOP sensor (Implandata Eyemate) not yet approved in the United States is a:* a. Sulcus based IOP sensor b. Iris based IOP sensor c. Intravitreal based IOP sensor d. Cornea based IOP sensor 4. The average corneal hysteresis for normal subjects in the United States is:* a. 8.5 b. 14 c. 10.5 d. 6 5. In a recent study published in Ophthalmology, glaucoma patients with IOP < 18 mm Hg that had low corneal hysteresis and thin corneas were at a ___% higher risk of progression?* a. 68% b. 5% c. 15% d. 95% 6. Corneal Hysteresis is:* a. the ability of the corneal tissue to dissipate energy. b. a substitute for the measurement of intraocular pressure. c. Is strongly correlated with central corneal thickness. d. Is strongly correclated with the size of the eye. 7. Latanoprostene bunod 0.024% (Vyzulta) mechanism of action is:* a. Decreases aqueous production. b. Increases both the unconventional and conventional outflow pathway. c. Increases the unconventional outflow pathway. d. Increases the conventional outflow pathway. 8. Netarsudil 0.02% (Rhopressa) mechanism of action is:* a. Rho Kinase inhibition to relax the trabecular meshwork to increase outflow. b. Rho Kinase inhibition to increase EVP (in animal studies). c. Norepinephrine transporter inhibition to increase aqueous production. d. Increase outflow through the uveoscleral pathway. 9. In the Mercury 1, Phase 3 FDA clinical trial, netarsudil 0.02% + latanoprost 0.005% (Rocklatan) reveled an IOP reduction of greater than or equal to 35% in what percentage of patients at 3 months:* a. 77% b. 46% c. 65% d. 88% 10. According to a study published in J. Glaucoma, 2009 by Arsani S, et al. what is the relative risk of glaucoma disease progression in patients with a diurnal IOP range of 5.4 mm Hg:* a. 1 b. 5.76 c. 10 d. 3.11 11. A 2016 study published in Ophthalmology in regard to a bimatoprost ring drug delivery device revealed:* a. The bimatoprost ring lowered IOP, revealed a low conjunctival hyperemia rate, and was shown to be noninferior to timolol. b. The bimatoprost ring did not lower IOP, revealed a low conjunctival hyperemia rate, and was shown to be noninferior to timolol. c. The bimatoprost ring lowered IOP, revealed a low conjunctival hyperemia rate, and did not demonstrate noninferiority to timolol. d. The bimatoprost ring did not lower IOP, revealed high conjunctival hyperemia rates, and did not demonstrate noninferiority to timolol. 12. According to a study by Nordstrom et al. published in the American Journal of Ophthalmology, what percentage of patients were nonadherent to their ocular medication dosing regimens:* a. 50% b. 60% c. 90% d. 10% 13. According to the Phase 3 (ARTEMIS 3) study what percentage of subjects went an additional 12 months without retreatment?* a. 10% b. 30% c. 60% d. 80% 14. The definition of Minimally Invasive Glaucoma Surgery is:* a. Procedures that have an ab-interno approach, are minimally atraumatic, with at least modest efficacy, extremely high safety and rapid recovery. b. Procedures that have an ab-interno approach, are minimally atraumatic, with amazing efficacy, low safety and rapid recovery. c. Procedures that have an ab-interno approach, are traumatic, with amazing efficacy, extremely high safety and slow recovery. d. Procedures that have an ab-interno approach, are minimally atraumatic, with at least modest efficacy, extremely low safety and slow recovery. 15. CSF pressure, according to studies by Berdahl and Ren, is _____ in patients with ocular hypertension compared to normal patients, primary open angle glaucoma patients, and normal tension glaucoma patients:* a. Lower b. Higher c. The same d. Fluctuates higher and lower 16. CSF pressure, according to studies by Berdahl and Ren, is _____ in patients with normal tension glaucoma compared to ocular hypertension, primary open angle glaucoma patients, and normal patients:* a. Lower b. Higher c. The same d. Fluctuates higher and lower 17. CSF pressure or Intracranial pressure tends to ____ with age:* a. Increase b. Not change c. Decrease d. There is no relationship with age and CSF/ICP pressure 18. According to the Phase 3 ARTEMIS study, bimatoprost SR reduced IOP by ___% over a 12 week primary efficacy period:* a. 30% b. 20% c. 40% d. 15% 19. Endothelial cell loss over 20 months in the Phase 3 (ARTEMIS) study was?* a. 15.3% b. 5.4% c. 51% d. 65.3% 20. According to a study by Wang, published in 2018, the percentage of subjects willing to have a subconjunctival drug insert was?* a. 32% b. 14% c. 52% d. 75% Personal InformationName* First Last Email* Phone*OE Tracker # License # Address* Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongo, Democratic Republic of theCongo, Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzech RepublicCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatini (Swaziland)EthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacauMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth KoreaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaRéunionSaint BarthélemySaint HelenaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth GeorgiaSouth KoreaSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan Mayen IslandsSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaVietnamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Payment InformationHiddenRetake Code Innovations in Glaucoma: Next Generation Technology, Medications, and Delivery | TQ Credit*After 1/19/2022, pricing will increase to $30. Price: (Past 60 Days) Innovations in Glaucoma: Next Generation Technology, Medications, and Delivery | TQ CreditThis course was presented over 60 days ago. Due to this late submission of TQ, your TQ credit price is $30. Price: Retake Discount Price: (Past 60 Days) Retake Discount Price: Payment MethodPayPal Checkout MasterCardVisaSupported Credit Cards: MasterCard, Visa Card Number Expiration Date Security Code Cardholder Name HiddenCourse Information (HIDDEN)HiddenCourse Name (HIDDEN) HiddenRetake Code (HIDDEN) HiddenQuiz URL (HIDDEN)Do not include ending backslash (aka no .com/) HiddenCE Hours Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website
